Andrew Day

Co-director (Christchurch)



Turner, D., Leach, S. T., Mack, D., Uusoue, K., McLernon, R., Hyams, J., … Day, A. S. (2010). Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: A prospective multicentre comparison of predicting outcomes and monitoring response. Gut59, 1207-1212. doi: 10.1136/gut.2010.211755

Leach, S. T., Mitchell, H. M., Eng, W. R., Zhang, L., & Day, A. S. (2008). Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Alimentary Pharmacology & Therapeutics28, 724-733. doi: 10.1111/j.1365-2036.2008.03796.x

Nahidi, L., Leach, S. T., Sidler, M. A., Levin, A., Lemberg, D. A., & Day, A. S. (2011). Osteoprotegerin in pediatric Crohn's disease and the effects of exclusive enteral nutrition. Inflammatory Bowel Diseases,17(2), 516-523. doi: 10.1002/ibd.21361

Sidler, M. A., Leach, S. T., & Day, A. S. (2008). Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflammatory Bowel Diseases14(3), 359-366. doi: 10.1002/ibd.20336

Critch, J., Day, A. S., Otley, A., King-Moore, C., Teitelbaum, J. E., & Shashidhar, H. (2012). Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. Journal of Pediatric Gastroenterology & Nutrition54(2), 298-305. doi: 10.1097/MPG.0b013e318235b397